Compare Amphastar Pharmaceuticals Inc (AMPH) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs JPMorgan Chase & Co — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while JPMorgan Chase & Co trades at $362.27 (market cap $956.39B). The key difference: JPMorgan Chase & Co is far larger — about 1107× Amphastar Pharmaceuticals Inc's market cap, and JPMorgan Chase & Co pays a 1.67% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | JPM | |
|---|---|---|
Market Cap | $863.95M | $956.39B |
Sector | Health | Financials |
52-Week High | $30.81 | $359.79 |
52-Week Low | $16.87 | $282.84 |
Enterprise Value | $1.26B | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
JPMorgan Chase & Co. (JPM) trades at $362.04, up 1.26% in the last session, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $374.18. Recent earnings beat expectations in Q1 and Q2 2026, with Q3 2026 results pending. The company maintains strong profitability metrics, including a net income margin of 33.38% and ROE of 18.43%, though cash flow trends show volatility amid macroeconomic uncertainties.
The stock presents a moderate buy opportunity with upside potential from earnings resilience and sector strength, but risks include geopolitical tensions, cybersecurity threats highlighted in recent news, and fluctuating cash flows. Investors should weigh analyst optimism against CEO warnings on economic challenges for balanced decision-making.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
